APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Mesalazine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oral Mesalazine Market Analysis and Forecast 2026-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchOral Mesalazine Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Mesalazine Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Oral Mesalazine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Mesalazine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Mesalazine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Oral Mesalazine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Oral Mesalazine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oral Mesalazine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oral Mesalazine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oral Mesalazine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Oral Mesalazine include Teva Pharmaceutical Industries, Ferring Global, AbbVie, Tillotts Pharma, Shire, Salix Pharmaceuticals, Nogra Pharma Limited, Morningside Healthcare and Dr. Falk Pharma UK, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Oral Mesalazine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oral Mesalazine, also provides the revenue of main regions and countries. Of the upcoming market potential for Oral Mesalazine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Mesalazine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oral Mesalazine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oral Mesalazine revenue, projected growth trends, production technology, application and end-user industry.

Oral Mesalazine Segment by Company

Teva Pharmaceutical Industries

Ferring Global

AbbVie

Tillotts Pharma

Shire

Salix Pharmaceuticals

Nogra Pharma Limited

Morningside Healthcare

Dr. Falk Pharma UK

Oral Mesalazine Segment by Type

Capsules

Granule

Tablets

Oral Mesalazine Segment by Application

Inflammatory Bowel Disease

Ulcerative Colitis

Crohn's Disease

Others

Oral Mesalazine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Mesalazine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Mesalazine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Mesalazine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oral Mesalazine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oral Mesalazine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Mesalazine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oral Mesalazine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Capsules Major Player Table 3. Granule Major Player Table 4. Tablets Major Player Table 5. Global Oral Mesalazine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Inflammatory Bowel Disease Major Player Table 7. Ulcerative Colitis Major Player Table 8. Crohn's Disease Major Player Table 9. Others Major Player Table 10. Oral Mesalazine Industry Trends Table 11. Oral Mesalazine Industry Drivers Table 12. Oral Mesalazine Industry Opportunities and Challenges Table 13. Oral Mesalazine Industry Restraints Table 14. Global Oral Mesalazine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Oral Mesalazine Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Oral Mesalazine Market Share by Region (2021-2026) Table 17. Global Oral Mesalazine Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Oral Mesalazine Market Share by Region (2027-2032) Table 19. Global Oral Mesalazine Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Oral Mesalazine Revenue Market Share by Players (2021-2026) Table 21. Global Oral Mesalazine Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Oral Mesalazine Key Players Headquarters & Area Served Table 23. Global Oral Mesalazine Players, Product Type & Application Table 24. Global Oral Mesalazine Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Oral Mesalazine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Oral Mesalazine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Oral Mesalazine Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Oral Mesalazine Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Oral Mesalazine Revenue Market Share by Type (2021-2026) Table 31. Global Oral Mesalazine Revenue Market Share by Type (2027-2032) Table 32. Global Oral Mesalazine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Oral Mesalazine Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Oral Mesalazine Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Oral Mesalazine Revenue Market Share by Application (2021-2026) Table 36. Global Oral Mesalazine Revenue Market Share by Application (2027-2032) Table 37. Teva Pharmaceutical Industries Company Information Table 38. Teva Pharmaceutical Industries Business Overview Table 39. Teva Pharmaceutical Industries Oral Mesalazine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Teva Pharmaceutical Industries Oral Mesalazine Product Portfolio Table 41. Teva Pharmaceutical Industries Recent Development Table 42. Ferring Global Company Information Table 43. Ferring Global Business Overview Table 44. Ferring Global Oral Mesalazine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Ferring Global Oral Mesalazine Product Portfolio Table 46. Ferring Global Recent Development Table 47. AbbVie Company Information Table 48. AbbVie Business Overview Table 49. AbbVie Oral Mesalazine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. AbbVie Oral Mesalazine Product Portfolio Table 51. AbbVie Recent Development Table 52. Tillotts Pharma Company Information Table 53. Tillotts Pharma Business Overview Table 54. Tillotts Pharma Oral Mesalazine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Tillotts Pharma Oral Mesalazine Product Portfolio Table 56. Tillotts Pharma Recent Development Table 57. Shire Company Information Table 58. Shire Business Overview Table 59. Shire Oral Mesalazine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Shire Oral Mesalazine Product Portfolio Table 61. Shire Recent Development Table 62. Salix Pharmaceuticals Company Information Table 63. Salix Pharmaceuticals Business Overview Table 64. Salix Pharmaceuticals Oral Mesalazine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Salix Pharmaceuticals Oral Mesalazine Product Portfolio Table 66. Salix Pharmaceuticals Recent Development Table 67. Nogra Pharma Limited Company Information Table 68. Nogra Pharma Limited Business Overview Table 69. Nogra Pharma Limited Oral Mesalazine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Nogra Pharma Limited Oral Mesalazine Product Portfolio Table 71. Nogra Pharma Limited Recent Development Table 72. Morningside Healthcare Company Information Table 73. Morningside Healthcare Business Overview Table 74. Morningside Healthcare Oral Mesalazine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Morningside Healthcare Oral Mesalazine Product Portfolio Table 76. Morningside Healthcare Recent Development Table 77. Dr. Falk Pharma UK Company Information Table 78. Dr. Falk Pharma UK Business Overview Table 79. Dr. Falk Pharma UK Oral Mesalazine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Dr. Falk Pharma UK Oral Mesalazine Product Portfolio Table 81. Dr. Falk Pharma UK Recent Development Table 82. North America Oral Mesalazine Revenue by Type (2021-2026) & (US$ Million) Table 83. North America Oral Mesalazine Revenue by Type (2027-2032) & (US$ Million) Table 84. North America Oral Mesalazine Revenue by Application (2021-2026) & (US$ Million) Table 85. North America Oral Mesalazine Revenue by Application (2027-2032) & (US$ Million) Table 86. North America Oral Mesalazine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. North America Oral Mesalazine Revenue by Country (2021-2026) & (US$ Million) Table 88. North America Oral Mesalazine Revenue by Country (US$ Million) & (2027-2032) Table 89. Europe Oral Mesalazine Revenue by Type (2021-2026) & (US$ Million) Table 90. Europe Oral Mesalazine Revenue by Type (2027-2032) & (US$ Million) Table 91. Europe Oral Mesalazine Revenue by Application (2021-2026) & (US$ Million) Table 92. Europe Oral Mesalazine Revenue by Application (2027-2032) & (US$ Million) Table 93. Europe Oral Mesalazine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. Europe Oral Mesalazine Revenue by Country (2021-2026) & (US$ Million) Table 95. Europe Oral Mesalazine Revenue by Country (US$ Million) & (2027-2032) Table 96. China Oral Mesalazine Revenue by Type (2021-2026) & (US$ Million) Table 97. China Oral Mesalazine Revenue by Type (2027-2032) & (US$ Million) Table 98. China Oral Mesalazine Revenue by Application (2021-2026) & (US$ Million) Table 99. China Oral Mesalazine Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Oral Mesalazine Revenue by Type (2021-2026) & (US$ Million) Table 101. Asia Oral Mesalazine Revenue by Type (2027-2032) & (US$ Million) Table 102. Asia Oral Mesalazine Revenue by Application (2021-2026) & (US$ Million) Table 103. Asia Oral Mesalazine Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Oral Mesalazine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Asia Oral Mesalazine Revenue by Region (US$ Million) & (2021-2026) Table 106. Asia Oral Mesalazine Revenue by Region (US$ Million) & (2027-2032) Table 107. SAMEA Oral Mesalazine Revenue by Type (2021-2026) & (US$ Million) Table 108. SAMEA Oral Mesalazine Revenue by Type (2027-2032) & (US$ Million) Table 109. SAMEA Oral Mesalazine Revenue by Application (2021-2026) & (US$ Million) Table 110. SAMEA Oral Mesalazine Revenue by Application (2027-2032) & (US$ Million) Table 111. SAMEA Oral Mesalazine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. SAMEA Oral Mesalazine Revenue by Country (2021-2026) & (US$ Million) Table 113. SAMEA Oral Mesalazine Revenue by Country (US$ Million) & (2027-2032) Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Oral Mesalazine Image Figure 2. Global Oral Mesalazine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Mesalazine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Capsules Image Figure 5. Granule Image Figure 6. Tablets Image Figure 7. Global Oral Mesalazine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Oral Mesalazine Market Size Share 2021 VS 2025 VS 2032 Figure 9. Inflammatory Bowel Disease Image Figure 10. Ulcerative Colitis Image Figure 11. Crohn's Disease Image Figure 12. Others Image Figure 13. Global Oral Mesalazine Market Size (US$ Million) & (2021-2032) Figure 14. Global Oral Mesalazine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Oral Mesalazine Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Oral Mesalazine Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Oral Mesalazine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Oral Mesalazine Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Oral Mesalazine Revenue Market Share by Type (2021-2032) Figure 21. Global Oral Mesalazine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oral Mesalazine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Oral Mesalazine Revenue Market Share by Application (2021-2032) Figure 24. North America Oral Mesalazine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Oral Mesalazine Revenue Share by Type (2021-2032) Figure 26. North America Oral Mesalazine Revenue Share by Application (2021-2032) Figure 27. North America Oral Mesalazine Revenue Share by Country (2021-2032) Figure 28. United States Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Oral Mesalazine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Oral Mesalazine Revenue Share by Type (2021-2032) Figure 33. Europe Oral Mesalazine Revenue Share by Application (2021-2032) Figure 34. Europe Oral Mesalazine Revenue Share by Country (2021-2032) Figure 35. Germany Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Oral Mesalazine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Oral Mesalazine Revenue Share by Type (2021-2032) Figure 45. China Oral Mesalazine Revenue Share by Application (2021-2032) Figure 46. Asia Oral Mesalazine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Oral Mesalazine Revenue Share by Type (2021-2032) Figure 48. Asia Oral Mesalazine Revenue Share by Application (2021-2032) Figure 49. Asia Oral Mesalazine Revenue Share by Region (2021-2032) Figure 50. Japan Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Oral Mesalazine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Oral Mesalazine Revenue Share by Type (2021-2032) Figure 58. SAMEA Oral Mesalazine Revenue Share by Application (2021-2032) Figure 59. SAMEA Oral Mesalazine Revenue Share by Country (2021-2032) Figure 60. Brazil Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Oral Mesalazine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Capsules
  • Granule
  • Tablets
Applications
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Crohn's Disease
  • Others
Companies covered
  • Teva Pharmaceutical Industries
  • Ferring Global
  • AbbVie
  • Tillotts Pharma
  • Shire
  • Salix Pharmaceuticals
  • Nogra Pharma Limited
  • Morningside Healthcare
  • Dr. Falk Pharma UK

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oral Mesalazine Market by Type
  3. 1.2.1 Global Oral Mesalazine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Capsules
  5. 1.2.3 Granule
  6. 1.2.4 Tablets
  7. 1.3 Oral Mesalazine Market by Application
  8. 1.3.1 Global Oral Mesalazine Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Inflammatory Bowel Disease
  10. 1.3.3 Ulcerative Colitis
  11. 1.3.4 Crohn's Disease
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Oral Mesalazine Market Dynamics
  1. 2.1 Oral Mesalazine Industry Trends
  2. 2.2 Oral Mesalazine Industry Drivers
  3. 2.3 Oral Mesalazine Industry Opportunities and Challenges
  4. 2.4 Oral Mesalazine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oral Mesalazine Market Perspective (2021-2032)
  2. 3.2 Global Oral Mesalazine Growth Trends by Region
  3. 3.2.1 Global Oral Mesalazine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oral Mesalazine Market Size by Region (2021-2026)
  5. 3.2.3 Global Oral Mesalazine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oral Mesalazine Revenue by Players
  2. 4.1.1 Global Oral Mesalazine Revenue by Players (2021-2026)
  3. 4.1.2 Global Oral Mesalazine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oral Mesalazine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oral Mesalazine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oral Mesalazine Key Players Headquarters & Area Served
  7. 4.4 Global Oral Mesalazine Players, Product Type & Application
  8. 4.5 Global Oral Mesalazine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oral Mesalazine Market CR5 and HHI
  11. 4.6.3 2025 Oral Mesalazine Tier 1, Tier 2, and Tier 3
5 Oral Mesalazine Market Size by Type
  1. 5.1 Global Oral Mesalazine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oral Mesalazine Revenue by Type (2021-2032)
  3. 5.3 Global Oral Mesalazine Revenue Market Share by Type (2021-2032)
6 Oral Mesalazine Market Size by Application
  1. 6.1 Global Oral Mesalazine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oral Mesalazine Revenue by Application (2021-2032)
  3. 6.3 Global Oral Mesalazine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceutical Industries
  2. 7.1.1 Teva Pharmaceutical Industries Company Information
  3. 7.1.2 Teva Pharmaceutical Industries Business Overview
  4. 7.1.3 Teva Pharmaceutical Industries Oral Mesalazine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Industries Oral Mesalazine Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 7.2 Ferring Global
  8. 7.2.1 Ferring Global Company Information
  9. 7.2.2 Ferring Global Business Overview
  10. 7.2.3 Ferring Global Oral Mesalazine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Ferring Global Oral Mesalazine Product Portfolio
  12. 7.2.5 Ferring Global Recent Developments
  13. 7.3 AbbVie
  14. 7.3.1 AbbVie Company Information
  15. 7.3.2 AbbVie Business Overview
  16. 7.3.3 AbbVie Oral Mesalazine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AbbVie Oral Mesalazine Product Portfolio
  18. 7.3.5 AbbVie Recent Developments
  19. 7.4 Tillotts Pharma
  20. 7.4.1 Tillotts Pharma Company Information
  21. 7.4.2 Tillotts Pharma Business Overview
  22. 7.4.3 Tillotts Pharma Oral Mesalazine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Tillotts Pharma Oral Mesalazine Product Portfolio
  24. 7.4.5 Tillotts Pharma Recent Developments
  25. 7.5 Shire
  26. 7.5.1 Shire Company Information
  27. 7.5.2 Shire Business Overview
  28. 7.5.3 Shire Oral Mesalazine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Shire Oral Mesalazine Product Portfolio
  30. 7.5.5 Shire Recent Developments
  31. 7.6 Salix Pharmaceuticals
  32. 7.6.1 Salix Pharmaceuticals Company Information
  33. 7.6.2 Salix Pharmaceuticals Business Overview
  34. 7.6.3 Salix Pharmaceuticals Oral Mesalazine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Salix Pharmaceuticals Oral Mesalazine Product Portfolio
  36. 7.6.5 Salix Pharmaceuticals Recent Developments
  37. 7.7 Nogra Pharma Limited
  38. 7.7.1 Nogra Pharma Limited Company Information
  39. 7.7.2 Nogra Pharma Limited Business Overview
  40. 7.7.3 Nogra Pharma Limited Oral Mesalazine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Nogra Pharma Limited Oral Mesalazine Product Portfolio
  42. 7.7.5 Nogra Pharma Limited Recent Developments
  43. 7.8 Morningside Healthcare
  44. 7.8.1 Morningside Healthcare Company Information
  45. 7.8.2 Morningside Healthcare Business Overview
  46. 7.8.3 Morningside Healthcare Oral Mesalazine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Morningside Healthcare Oral Mesalazine Product Portfolio
  48. 7.8.5 Morningside Healthcare Recent Developments
  49. 7.9 Dr. Falk Pharma UK
  50. 7.9.1 Dr. Falk Pharma UK Company Information
  51. 7.9.2 Dr. Falk Pharma UK Business Overview
  52. 7.9.3 Dr. Falk Pharma UK Oral Mesalazine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Dr. Falk Pharma UK Oral Mesalazine Product Portfolio
  54. 7.9.5 Dr. Falk Pharma UK Recent Developments
8 North America
  1. 8.1 North America Oral Mesalazine Revenue (2021-2032)
  2. 8.2 North America Oral Mesalazine Revenue by Type (2021-2032)
  3. 8.2.1 North America Oral Mesalazine Revenue by Type (2021-2026)
  4. 8.2.2 North America Oral Mesalazine Revenue by Type (2027-2032)
  5. 8.3 North America Oral Mesalazine Revenue Share by Type (2021-2032)
  6. 8.4 North America Oral Mesalazine Revenue by Application (2021-2032)
  7. 8.4.1 North America Oral Mesalazine Revenue by Application (2021-2026)
  8. 8.4.2 North America Oral Mesalazine Revenue by Application (2027-2032)
  9. 8.5 North America Oral Mesalazine Revenue Share by Application (2021-2032)
  10. 8.6 North America Oral Mesalazine Revenue by Country
  11. 8.6.1 North America Oral Mesalazine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oral Mesalazine Revenue by Country (2021-2026)
  13. 8.6.3 North America Oral Mesalazine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oral Mesalazine Revenue (2021-2032)
  2. 9.2 Europe Oral Mesalazine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oral Mesalazine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oral Mesalazine Revenue by Type (2027-2032)
  5. 9.3 Europe Oral Mesalazine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oral Mesalazine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oral Mesalazine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oral Mesalazine Revenue by Application (2027-2032)
  9. 9.5 Europe Oral Mesalazine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oral Mesalazine Revenue by Country
  11. 9.6.1 Europe Oral Mesalazine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oral Mesalazine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oral Mesalazine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oral Mesalazine Revenue (2021-2032)
  2. 10.2 China Oral Mesalazine Revenue by Type (2021-2032)
  3. 10.2.1 China Oral Mesalazine Revenue by Type (2021-2026)
  4. 10.2.2 China Oral Mesalazine Revenue by Type (2027-2032)
  5. 10.3 China Oral Mesalazine Revenue Share by Type (2021-2032)
  6. 10.4 China Oral Mesalazine Revenue by Application (2021-2032)
  7. 10.4.1 China Oral Mesalazine Revenue by Application (2021-2026)
  8. 10.4.2 China Oral Mesalazine Revenue by Application (2027-2032)
  9. 10.5 China Oral Mesalazine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oral Mesalazine Revenue (2021-2032)
  2. 11.2 Asia Oral Mesalazine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oral Mesalazine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oral Mesalazine Revenue by Type (2027-2032)
  5. 11.3 Asia Oral Mesalazine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oral Mesalazine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oral Mesalazine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oral Mesalazine Revenue by Application (2027-2032)
  9. 11.5 Asia Oral Mesalazine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oral Mesalazine Revenue by Country
  11. 11.6.1 Asia Oral Mesalazine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oral Mesalazine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oral Mesalazine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oral Mesalazine Revenue (2021-2032)
  2. 12.2 SAMEA Oral Mesalazine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oral Mesalazine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oral Mesalazine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oral Mesalazine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oral Mesalazine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oral Mesalazine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oral Mesalazine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oral Mesalazine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oral Mesalazine Revenue by Country
  11. 12.6.1 SAMEA Oral Mesalazine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oral Mesalazine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oral Mesalazine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst